The stock of Ionis Pharmaceuticals Inc (IONS) has seen a -4.73% decrease in the past week, with a -2.66% drop in the past month, and a -20.24% decrease in the past quarter. The volatility ratio for the week is 2.19%, and the volatility levels for the past 30 days are at 2.50% for IONS. The simple moving average for the last 20 days is -4.70% for IONS’s stock, with a simple moving average of -9.87% for the last 200 days.
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
Company’s 36-month beta value is 0.41.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for IONS is 133.94M, and currently, short sellers hold a 7.11% ratio of that floaft. The average trading volume of IONS on April 18, 2024 was 1.15M shares.
IONS) stock’s latest price update
Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s stock price has gone decline by -1.52 in comparison to its previous close of 41.54, however, the company has experienced a -4.73% decrease in its stock price over the last five trading days. PRNewsWire reported 2024-04-01 that CARLSBAD, Calif., April 1, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024 45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with Wolfe Research repeating the rating for IONS by listing it as a “Outperform.” The predicted price for IONS in the upcoming period, according to Wolfe Research is $58 based on the research report published on April 10, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $52. The rating they have provided for IONS stocks is “Buy” according to the report published on January 02nd, 2024.
BofA Securities gave a rating of “Neutral” to IONS, setting the target price at $52 in the report published on October 23rd of the previous year.
IONS Trading at -8.36% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.86% of loss for the given period.
Volatility was left at 2.50%, however, over the last 30 days, the volatility rate increased by 2.19%, as shares sank -2.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.24% lower at present.
During the last 5 trading sessions, IONS fell by -4.73%, which changed the moving average for the period of 200-days by -0.29% in comparison to the 20-day moving average, which settled at $42.87. In addition, Ionis Pharmaceuticals Inc saw -19.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Baroldi Joseph, who sale 4,006 shares at the price of $41.60 back on Apr 16 ’24. After this action, Baroldi Joseph now owns 19,631 shares of Ionis Pharmaceuticals Inc, valued at $166,641 using the latest closing price.
Birchler Brian, the EVP, Corp and Development Ops of Ionis Pharmaceuticals Inc, sale 905 shares at $41.66 during a trade that took place back on Apr 16 ’24, which means that Birchler Brian is holding 46,156 shares at $37,698 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.45 for the present operating margin
- 0.99 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.46. The total capital return value is set at -0.14. Equity return is now at value -76.29, with -13.25 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at 3.76. The interest coverage ratio of the stock is -4.86.
Currently, EBITDA for the company is -322.84 million with net debt to EBITDA at -3.76. When we switch over and look at the enterprise to sales, we see a ratio of 8.91. The receivables turnover for the company is 8.05for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.90.
Conclusion
In a nutshell, Ionis Pharmaceuticals Inc (IONS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
